

Supplementary Table 1. Studies with liver fibrosis as secondary endpoint

Cause	Drug name/Treatment	Efficacy	Year of completion/publication	Phase	No. of patients	NCT (Ref.)
HCV (Non-antiviral agents)						
HCV	PF-04136309 (CCR2 antagonist) vs plac; 4 wk, r, db	Pending	2012	2	24	01226797
HCV, post transplantation	Rifaximin (gut specific antibiotic for hepatic encephalopathy) vs plac; 1 yr, r, db	Pending	2014	2	60	01603108
HCV/HIV, coinfectd	GS-6624 (anti-LOXL2 mAb); 36 wk, nr, ol	Pending	2014	2	30	01707472
HCV (Antiviral agents)						
HCV	IFN α lozenges vs plac lozenges; 12 wk, r, db	Pending	2012	2	169	00695019
HCV/HIV, coinfectd	Peg-IFN α -2b + R + Boceprevir (NS3 protease inhibitor); 24 wk, nr, ol	Pending	2015	3	310	01482767
HBV, HDV (Antiviral agents)						
HBV	Peg-IFN α -2b; 24 wk, r, ol	No effect	2009	3	671	00536263
HDV	Peg-IFN α -2a, Tenofovir vs plac; 96 wk, r, db	Pending	2017	2	70	00932971
Primary biliary cirrhosis (PBC)						
PBC	Bezafibrate (PPAR α - γ - δ agonist) vs plac; 2 yr, r, db	Pending	2015	3	92	01654731
	Obeticholic acid (FXR agonist) vs plac; 6 and 12 mo, r, db	Pending	2018	3	180	01473524
Non-alcoholic steatohepatitis (NASH)						
NASH	Metformin vs Vit. E; 1 yr, r, ol	Significant decrease (10%) in fibrosis score; $p=0.012$	2005	-	55	(Bugianesi E, et al., 2005)
	Vit. E + Ascorbic acid vs plac; 1 and 2 yr, r, db	No effect	2006	2/3	90	00655018 (Nobili V, et al., 2006)
	Rosi; 1 yr, r, db	No study results reported	2007	2	63	00492700
	Pio vs Vit. E vs plac; 96 wk, r, db	No significant effect on fibrosis: improvement in 31/70 (Pio) vs 33/80 (Vit. E) vs 22/72 (plac); $p=0.12$ (Pio); $p=0.24$ (Vit. E) vs plac	2009/2009	3	247	00063622 (Chalasan i NP, et al., 2009)
	Rimonabant (SR141716, CB1R antagonist) vs plac; 2 yr, r, db	Prematurely ended due to clinical depression	2009	3	165	00576667
	Rimonabant (SR141716) vs plac; 18 mo, r, db	Prematurely ended due to clinical depression	2009	3	89	00577148
	Rosi; 1 yr, r, ol	No effect	2010	-	53	(Ratziu V, et al., 2010)
	Efamaz (Omega-3 fatty acids); 3 mo, r, db	No results reported	2010	2	58	00819338
	Vit. E vs Metformin vs plac; 2 yr, r, db	No effect	2011		173	(Lavine J, et al., 2011)
	Oltipraz (antiproliferative drug) vs plac; 24 wk, r, db	No results reported	2011	2	60	01373554
	Silymarin (anti-oxidant) vs plac; 48-50 wk, r, db	Pending	2012	2	78	00680407
	Hepar-P \dagger vs plac; 48 wk, r, db	Pending	2013	2	50	01680003
	Delayed release cysteine bitartrate vs plac; 52 wk, r, db	Pending	2014	2/3	160	01529268
	Vit. E vs weight reduction and exercise; 1 yr, nr, ol	No results reported	2010	2	60	00152815
NASH/HCV	Orlistat (anti-obesity drug) + Peg-IFN α -2a vs Orlistat + Peg-IFN α -2a; 48 wk, r, db	Pending	2009	4	30	00207311

CB1R, cannabinoid receptor type 1; CCR2, CC chemokine receptor type 2; db, double-blind; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; HBV, hepatitis B; HCV, hepatitis C; HDV, hepatitis D; Hepar-P \dagger , phytopharmaceutical supplement, consisting of corilagin and Phyllanthus flavonoids; HIV, human immunodeficiency virus; IFN, interferon; LOXL2, lysyl oxidase-like 2; NCT, number at ClinicalTrials.gov; nr, non-randomized; ol, open-label; PBC, primary biliary cirrhosis; Peg-IFN, pegylated interferon; plac, placebo; Pio, pioglitazone; PPAR, peroxisome proliferator-activated receptor; r, randomized; R, ribavirin; Rosi, rosiglitazone.